cid:image001.jpg@01D158FE.B69B8D00

S E M I N A R & V I S I T I N G S P E A K E R S E R I E S

D AT E

Friday, April 27th, 2018

9 am

L O C AT I O N

236/238 PsycHealthBldg.

S P E A K E R

http://umanitoba.ca/faculties/health_sciences/medicine/units/pharmacology/f aculty_members/8300.html Dr. Sachin Katyal CIHR and TFRI New Investigator,

Assistant Professor, Department of Pharmacology and Therapeutics, University of Manitoba;

Senior Scientist, Research Institute in Oncology and Hematology (formerly MICB), CancerCare Manitoba

675 McDermot Ave, Winnipeg, MB, R3E 0V9

Sachin.Katyal@umanitoba.ca

ph.: 204-787-2765, fax: 204-787-2190

T O P I C Targeting resistant glioblastoma multiforme (rGBM) through suppression of overactive DNA repair activity

B I O Sachin Katyal received his B.Sc. (Biochemistry) from the University of Alberta and received his Ph.D. (Oncology) at the Cross Cancer Institute and the University of Alberta. His post-doctoral training, at St. Jude Children’s Research Hospital, in the area of DNA damage and repair in neurodevelopment and neuro-oncology was done in the lab of Dr. Peter McKinnon; work that led to publications in internationally-renowned journals such as Nature, Nature Neuroscience and EMBO J. In 2013, Dr. Katyal began his independent academic research position at the University of Manitoba and CancerCare Manitoba where he is an Assistant Professor within the Department of Pharmacology and Therapeutics (D-PT) and, a Senior Scientist within the Research Institute of Oncology and Hematology (RIOH). Dr. Katyal’s research is CIHR- and TFRI-funded; he is the recipient of the CIHR Institute of Cancer Research 2014 Early Career Award in Cancer Research, a CIHR New Investigator award and most recently a TFRI New Investigator Award to counteract resistant Glioblastoma Multiforme (GBM). He serves on several scientific review committees for international academic journals and grant review panels. Sachin has also established industrial partnerships, which have facilitated the development of innovative technology and methodology to accelerate his DNA damage repair research program. These were instrumental for his recently-funded CFI infrastructure award to develop a novel high-throughput genotoxicity and drug screening facility to understand and identify new therapies against brain tumours and leukemia. Sachin is also actively involved in trainee development, mentorship and career progression through various University-wide initiatives, courses and workshops.

L E A R N I N G O B J E C T I V E S

1. To understand the function of DNA damage repair pathways during neurodevelopment. 2. To identify biochemical (DNA repair) mechanisms that cancerous cells use to mitigate the effectiveness of chemotherapeutics in neural tumours. 3. To describe new high-throughput DNA damage analysis methodology. 4. To functionalize this methodology into a novel drug screening and DNA damage analysis platform to interrogate tumour chemoresistance and to develop personalized “quick-to-clinic” anti-GBM treatments via drug repurposing studies.

/sent on behalf of

Dr. Eftekhar Eftekharpour Coordinator, Seminar & Visiting Speaker Series Manitoba Neuroscience Network E: Eftekhar.Eftekharpour@umanitoba.ca

Kelly Jorundson Coordinator, Membership & Operations Manitoba Neuroscience Network

Email: kjorund@sbrc.ca Tel: 204.235.3939 Fax: 204.237.4092

St. Boniface Hospital Albrechtsen Research Centre Room R4046 - 351 Taché Avenue, Winnipeg, MB R2H 2A6 CANADA

This email and any attachments may contain confidential, personal and/or privileged information intended for a specific individual and purpose. If you are not the intended recipient, you are hereby notified that any disclosure, copying, retaining, distribution, access, use or modification of the contents of this e-mailed information is strictly prohibited. If you receive this communication in error, please notify the sender immediately and delete or destroy the email message and any attachments or copies. ******************************************

http://www.manitobaneuroscience.ca/ cid:image003.jpg@01D159B3.9F0B9710

https://www.facebook.com/manitobaneuroscience/?fref=ts cid:image007.png@01D29326.7E26D480 https://www.instagram.com/manitobaneuroscience/ cid:image009.jpg@01D29326.7E26D480 https://twitter.com/manitobaneuro cid:image010.png@01D29326.7E26D480